Following NICE’s rejection last week for Tagrisso, AstraZeneca argues that the health technology appraisal body was wrong not to take the company’s real-world data into account when considering whether the lung cancer drug should be granted “end of life” status.
AstraZeneca has said it will appeal against last week’s decision by the National Institute for Health and Care Excellence (NICE) to recommend that its drug, Tagrisso, should not be used on England’s National Health Service as a first line treatment for a certain type of lung cancer.
NICE issued final guidance on 5 July saying that Tagrisso (osimertinib) was not an acceptable use of NHS resources for adults with untreated locally-advanced or metastatic epidermal growth factor receptor...
Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.
